Purpose-built, high-precision MRD testing
Haystack MRD™
Exceptional sensitivity
Minimal residual disease (MRD) testing demands high-sensitivity circulating tumor DNA (ctDNA) detection. Haystack MRD is a tumor-informed, next-generation MRD test that detects ultralow levels of ctDNA to uncover residual disease after definitive surgery.
Residual disease detection
Go beyond traditional methods for adjuvant chemotherapy guidance.
Treatment response assessment
Track ctDNA levels during adjuvant chemotherapy to monitor treatment response.
Disease recurrence surveillance
Detect disease relapse earlier than traditional methods.

Transformative precision
Dive deeper
Haystack Oncology was founded to dramatically improve patient outcomes by helping doctors optimize treatment strategies using transformative precision oncology. Learn how we support clinicians and biopharma in our mission by providing ultrasensitive MRD testing for informed clinical management and therapeutic development.
The difference
Why Haystack MRD
Confident MRD results
Ultrasensitive ctDNA testing delivers the insights you need to make confident treatment decisions.
Transformative technology
Packed with the power of Quest
Haystack MRD offers end-to-end MRD test reliability, powered by Quest Diagnostics credentialed staff, labs, logistics, service, reporting, and technology. Plus, the transition between Haystack MRD and Quest’s other advanced oncology testing is seamless for easier, more streamlined patient care. Visit questdiagnostics.com to learn more.

Haystack MRD
In the news

Learn about Haystack MRD™ at ASCO 2025

Haystack MRD™ by Quest Diagnostics® at SSO 2025
